10/30/2023 0 Comments Andexxa cost![]() ![]() Then it took off to well above $50 on over-optimism for its pipeline. It went public in 2013 just below $15, quickly went to a premium, then bounced around mostly in the $20s until early 2015. PTLA may now be seasoned enough to have worked off the IPO-related boom and bust. I have owned PTLA nearly continuously for over 2 years, though in widely varying quantities, and thought that management has a realistic plan for success for its lead product, AndexXa and that for investment purposes, the Street finally is going to treat the stock as primarily an AndexXa story and secondarily betrixaban. More importantly, the company provided updates on its two potentially commercializable products as well as on its cancer drug that is now in a Phase 2 study. Junior biotech Portola Pharmaceuticals ( NASDAQ: PTLA) reported earnings after the close Tuesday. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |